NCT06643130
Recruiting
Phase 3
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
JW Pharmaceutical1 site in 1 country162 target enrollmentDecember 2, 2024
Overview
- Phase
- Phase 3
- Intervention
- JW0104+C2402
- Conditions
- Hypertension
- Sponsor
- JW Pharmaceutical
- Enrollment
- 162
- Locations
- 1
- Primary Endpoint
- Change from baseline in msSBP (Systolic Blood Pressure)
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
Detailed Description
To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with hypertension and dyslipidemia
Exclusion Criteria
- •The subject not meet the specified msBP and LDL-C level
Arms & Interventions
JW0104+C2402
JW0104+C2402, 8 weeks, QD (Quaque Die)
Intervention: JW0104+C2402
JW0104+C2403
JW0104+C2403, 8 weeks, QD
Intervention: JW0104+C2403
C2402
C2402, 8 weeks, QD
Intervention: C2402
Outcomes
Primary Outcomes
Change from baseline in msSBP (Systolic Blood Pressure)
Time Frame: week 8
Check msSBP
Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)
Time Frame: week 8
Check LDL-C
Secondary Outcomes
- change from baseline in msSBP(week 4)
- Change and percent change from baseline in LDL-C(week 4)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and HypertensionDyslipidemiaHypertensionNCT05331014JW Pharmaceutical155
Completed
Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125AHypercholesterolemia, DyslipidemiaNCT05970679Daewon Pharmaceutical Co., Ltd.252
Unknown
Phase 3
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue SarcomaSoft Tissue SarcomaNCT05121350Chia Tai Tianqing Pharmaceutical Group Co., Ltd.256
Completed
Phase 3
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid TumorsBone MetastasesNCT04812509Mabwell (Shanghai) Bioscience Co., Ltd.708
Not yet recruiting
Phase 3
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergencyHypertensive EmergencyNCT05922436Qilu Pharmaceutical (Hainan) Co., Ltd.378